(Reuters) – Moderna Inc said Friday it has sought US approval to use its Omicron-targeted COVID vaccine in adolescents and children.
The company is seeking authorization for the emergency use of its updated vaccine in two age groups: adolescents ages 12 to 17 and children ages six to 11.
The bivalent vaccine application for children between six months and under six years of age is expected to be completed later this year, the company said in a tweet.
Earlier this week, the US Centers for Disease Control and Prevention said they expect COVID-19 vaccine boosters targeting circulating variants of the virus to be available to children ages 5-11 by mid-October.
Moderna’s mRNA-1273.222, a bivalent booster injection, contains the dominant BA.4/BA.5 variants along with the parental coronavirus strain.
The updated vaccine is already approved for adults, while competitor Pfizer’s bivalent vaccine has been approved as a booster dose for children over the age of 12.
The U.S. government has ordered more than 170 million updated vaccine boosters for this fall and said it shipped more than 25 million doses on Tuesday for distribution.
(Reporting by Mrinalika Roy in Bengaluru; editing by Shinjini Ganguli)